【摘要】 271例Ⅱ型糖尿病患者经用糖适平（GL）治疗5或7个月后,空腹及餐后血糖、HbA₁、尿糖及尿蛋白均较治疗前明显降低（P<0.01）.空腹及餐后血糖分别较治前平均降低21.48％和25.41％。GL治疗总有效率为85.6％。低血糖反应发生率为0.7％。其他副反应有嗜睡6例,瘙痒、腹胀和面部刺痛各1例。血像及肝肾功能无特殊变化。本药适应证除与一般磺脲类（SU）相同外,尤适于:（1）老年糖尿病;（2）糖尿病伴轻至中度肾功能减退;（3）用其他SU反复有低血糖发作者;（4）其他SU失效者。GL剂量为112.40±66.50mg/d（15～270mg/d）,较国外报告为高。更多还原

【Abstract】 271 cases of NIDDM treated for 5 or 7 months with Glurenorm (GL) were studied. After 5-month treatment with GL the FBG and PBG decreased significantly from 9.87±0.18 to 7.78±0.11 mmol/L (P<0.01), and from 15.27±0.30 to 11.39±0.21 mmol/L (P<0.01), respectively. So did the HbA1,UG and UP. A 5-month treatment of GL yielded an effective glucose-lowering rate of 85.6% with an average daily dose of 112.4±66.5 mg (15-270 mg). The occurrence of hypoglycemic events (mild) was 0.7%. No other serious side effects were found. Thus, GL is a safe and effective sulfonylurea (SU) with very low risk of hypoglycemia. It can be indicated for all NIDDM patients suitable for other SU, and especially appropriate for: 1) elderly diabetics; 2) diabetic nephropalhy with mild to moderate renal insufficiency; 3) recurrent and severe episodes of hypoglycemia after treatment with other SU.更多还原